ALLO Insider Trading Activity and SEC Form 4 Filings
ALLO insider trading summary
Over the past 12 months, insiders at Allogene Therapeutics, Inc. (ALLO) reported 15 sales worth $669K by 6 insiders and no open-market purchases on SEC Form 4. Net insider selling was $669K.
Latest ALLO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 21, 2026 | Geoffrey M. Parker | Chief Financial Officer | Sell | $49K (36,342 @ $1.34) |
| Aug 21, 2026 | Earl Martin Douglas | SVP, General Counsel | Sell | $63K (29,697 @ $2.12) |
| Apr 21, 2026 | Annie Yoshiyama | SVP, Finance | Sell | $22K (9,586 @ $2.31) |
| Mar 31, 2026 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sell | $7K (2,867 @ $2.50) |
| Mar 16, 2026 | David D Chang | President and CEO | Sell | $118K (47,763 @ $2.47) |
| Mar 16, 2026 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sell | $12K (4,835 @ $2.47) |
| Mar 2, 2026 | Benjamin Machinas Beneski | SVP, Chief Technical Officer | Sell | $19K (7,132 @ $2.60) |
| Feb 2, 2026 | Earl Martin Douglas | SVP, General Counsel | Sell | $40K (22,900 @ $1.76) |
| Feb 2, 2026 | Annie Yoshiyama | SVP, Finance | Sell | $7K (4,167 @ $1.72) |
| Feb 2, 2026 | Geoffrey M. Parker | Chief Financial Officer | Sell | $42K (24,001 @ $1.76) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.